News
-
-
PRESS RELEASE
Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare as Sanofi transfers a 50% stake in Opella. Opella to become a standalone leader backed by Sanofi's strategic support and guidance -
PRESS RELEASE
EQS-Adhoc: FRIEDRICH VORWERK grows by 32% in the third quarter to €145m in revenues with an EBITDA margin of 17.5% and raises its 2024 forecast to €430-460m in revenues with an EBITDA margin of 14-15 %
FRIEDRICH VORWERK reports 32% revenue growth in Q3, reaching €145m with EBITDA margin of 17.5%. Raises 2024 forecast to €430-460m revenues with 14-15% EBITDA margin -
-
PRESS RELEASE
Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment
Relief Therapeutics receives Notice of Allowance for European Patent covering RLF-TD011 for Epidermolysis Bullosa wound treatment. The patent will protect RLF-TD011 until 2040 in key European countries, with applications under review in other major markets -
REGULATED PRESS RELEASE
ICADE - CP - Activité au 30 septembre 2024
-
-
PRESS RELEASE
HBM Healthcare Investments publishes Half-Year Report as at 30 September 2024 with key figures for the first six months of the 2024/2025 financial year
HBM Healthcare Investments AG releases Half-Year Report, showing a profit of CHF 23 million with positive NAV and share price growth. Private and public companies both contribute to earnings -
PRESS RELEASE
HBM Healthcare Investments publishes Half-Year Report as at 30 September 2024 with key figures for the first six months of the 2024/2025 financial year
HBM Healthcare Investments reports CHF 23 million profit and 1.5% NAV increase for the first six months ending September 2024, despite 5% negative currency impact -
PRESS RELEASE
We are delighted to invite you to our 3Q Trading Update Presentation Webcast: Thursday, October 31 2024 at 14:30 CET
Avolta AG invites you to the 3Q Trading Update Webcast on Oct 31 2024, 14:30 CET. CEO Xavier Rossinyol and CFO Yves Gerster will present in English. Q&A session included
